Orthofix Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Net Sales: $196.4 million, up 3% year-over-year (constant currency).

Spine Fixation Sales: Grew 6% globally; U.S. sales increased 4%.

Therapeutic Solutions: Net sales of $57.8 million, up 5%.

Limb Reconstruction: Net sales of $32.8 million, up 3%.

Gross Margin: Pro forma non-GAAP adjusted gross margin at 70.7%, a 40 basis point improvement.

Adjusted EBITDA: $9.7 million, in line with expectations.

Cash Position: $120.9 million in total cash, including restricted cash.

2Strategic Updates and Business Highlights

Leadership Changes: Simplified spine leadership structure to enhance decision-making and accountability.

Distributor Performance: Top 30 U.S. distributors achieved 27% year-over-year growth, indicating successful strategy implementation.

Innovation Pipeline: Strong focus on the upcoming launch of the VIRATA system and continued adoption of the 7D FLASH navigation system.

Biologics Strategy: Realigned under a new leadership to improve execution and expand market penetration.

3Forward Guidance and Outlook

Full Year 2026 Guidance: Reaffirmed net sales expected between $850 million and $860 million, representing approximately 5.5% growth at the midpoint.

Growth Expectations: Anticipated 5% growth in the first half and 6% in the second half of 2026.

Adjusted EBITDA Guidance: Expected between $95 million and $98 million, with margin expansion projected.

4Bad News, Challenges, or Points of Concern

Impact of External Factors: Minimal impact from geopolitical events in the Middle East; however, some timing issues affected sales.

Biologics Performance: Although showing improvement, the segment is still recovering from previous challenges and requires further execution enhancements.

Limb Reconstruction Sales: Flat U.S. performance due to timing of capital sales and product line sunsetting, although expected to return to double-digit growth in the second half of 2026.

5Notable Q&A Insights

U.S. Spine Growth: Management expects acceleration in growth due to the annualization of distributor transitions and upcoming product launches.

Q2 Growth Projections: Anticipated around 6% constant currency growth, following a 3% growth in Q1.

Biologics Leadership: Realignment under a seasoned leader aims to enhance growth, with expectations to return to market growth by year-end.

Distributor Strategy: Plans to apply successful strategies from top distributors to lower-tier distributors to enhance overall performance. Overall, Orthofix reported a solid start to 2026 with a focus on strategic execution, innovation, and improving operational metrics, while also acknowledging areas needing further attention and improvement.